184 related articles for article (PubMed ID: 14616939)
41. HER2 overexpressing metastatic breast cancer.
Spigel DR; Burstein HJ
Curr Treat Options Oncol; 2002 Apr; 3(2):163-74. PubMed ID: 12057079
[TBL] [Abstract][Full Text] [Related]
42. New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin).
Nabholtz JM; Slamon D
Semin Oncol; 2001 Feb; 28(1 Suppl 3):1-12. PubMed ID: 11301369
[TBL] [Abstract][Full Text] [Related]
43. Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK.
Papazisis KT; Habeshaw T; Miles DW;
Int J Clin Pract; 2004 Jun; 58(6):581-6. PubMed ID: 15311558
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Zhu ZL; Zhang J; Chen ML; Li K
Asian Pac J Cancer Prev; 2013; 14(12):7111-6. PubMed ID: 24460260
[TBL] [Abstract][Full Text] [Related]
45. Docetaxel and herceptin: foundation for future strategies.
Pegram MD
Oncologist; 2001; 6 Suppl 3():22-5. PubMed ID: 11346681
[TBL] [Abstract][Full Text] [Related]
46. [Trastuzumab (Herceptin)].
Tokuda Y; Suzuki Y; Saitou Y; Ohta M; Tajima T
Gan To Kagaku Ryoho; 2002 Apr; 29(4):645-52. PubMed ID: 11977556
[TBL] [Abstract][Full Text] [Related]
47. [Use of trastuzumab in the therapy of breast cancer].
Riemer AB; Zielinski CC
Ther Umsch; 2008 Apr; 65(4):217-22. PubMed ID: 18622914
[TBL] [Abstract][Full Text] [Related]
48. [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer].
Zhou NN; Lin XB; Liu DG; Teng XY; Zhong JT; Jiang WQ
Ai Zheng; 2008 Sep; 27(9):947-50. PubMed ID: 18799033
[TBL] [Abstract][Full Text] [Related]
49. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Joensuu H; Kellokumpu-Lehtinen PL; Bono P; Alanko T; Kataja V; Asola R; Utriainen T; Kokko R; Hemminki A; Tarkkanen M; Turpeenniemi-Hujanen T; Jyrkkiö S; Flander M; Helle L; Ingalsuo S; Johansson K; Jääskeläinen AS; Pajunen M; Rauhala M; Kaleva-Kerola J; Salminen T; Leinonen M; Elomaa I; Isola J;
N Engl J Med; 2006 Feb; 354(8):809-20. PubMed ID: 16495393
[TBL] [Abstract][Full Text] [Related]
50. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
51. Advances in first-line treatment for patients with HER-2+ metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Oncologist; 2012; 17(5):631-44. PubMed ID: 22523199
[TBL] [Abstract][Full Text] [Related]
52. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
Ardavanis A; Kountourakis P; Kyriakou F; Malliou S; Mantzaris I; Garoufali A; Yiotis I; Scorilas A; Baziotis N; Rigatos G
Oncologist; 2008 Apr; 13(4):361-9. PubMed ID: 18448549
[TBL] [Abstract][Full Text] [Related]
53. [Rationale for Herceptin in the clinical use].
Ebi H; Sasaki Y
Nihon Rinsho; 2002 Mar; 60(3):463-7. PubMed ID: 11904959
[TBL] [Abstract][Full Text] [Related]
54. Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan.
Tokuda Y; Suzuki Y; Ohta M; Saito Y; Kubota M; Tajima T; Umemura S; Osamura RY
Breast Cancer; 2001; 8(4):310-5. PubMed ID: 11791123
[TBL] [Abstract][Full Text] [Related]
55. Clinical trials of Herceptin(trastuzumab).
Baselga J
Eur J Cancer; 2001 Jan; 37 Suppl 1():S18-24. PubMed ID: 11167087
[TBL] [Abstract][Full Text] [Related]
56. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials.
Sparano JA
Semin Oncol; 2001 Feb; 28(1 Suppl 3):20-7. PubMed ID: 11301371
[TBL] [Abstract][Full Text] [Related]
57. [Molecular-targeted agents in breast cancer].
Tokuda Y; Saito Y; Suzuki Y
Gan To Kagaku Ryoho; 2006 Jun; 33(6):747-53. PubMed ID: 16770092
[TBL] [Abstract][Full Text] [Related]
58. Ongoing and planned trials of hormonal therapy and trastuzumab.
Nicholson BP
Semin Oncol; 2000 Dec; 27(6 Suppl 11):33-7; discussion 92-100. PubMed ID: 11236026
[TBL] [Abstract][Full Text] [Related]
59. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
[TBL] [Abstract][Full Text] [Related]
60. The current status of docetaxel for metastatic breast cancer.
Esteva FJ
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):17-26. PubMed ID: 12108894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
